The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).
 
Luciana Molinero
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Patents, Royalties, Other Intellectual Property - P35974-US Patent Application Inventorship
 
Xiangnan Guan
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Regula Deurloo
Employment - F. Hoffmann LaRoche
Stock and Other Ownership Interests - Roche
 
Yosi Gozlan
Employment - Immunai
 
Hila Sharim
Employment - Immunai
Stock and Other Ownership Interests - Immunai
 
Leisha A. Emens
Leadership - Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer
Stock and Other Ownership Interests - Molecuvax
Consulting or Advisory Role - Abbvie; Bristol Meyers Squibb; Chugai Pharma; CytomX Therapeutics; DNAMx; Genentech/Roche; Gilead Sciences; GPCR Therapeutics; Immune-Onc Therapeutics; Immunitas; Lilly; Macrogenics; Molecuvax; Replimune; Shionogi; Silverback Therapeutics
Research Funding - Abbvie; Aduro Biotech; AstraZeneca; Bolt Biotherapeutics; Bristol Myers Squibb; Compugen; Corvus Pharmaceuticals; CytomX Therapeutics; EMD Serono; Genentech; Immune-Onc Therapeutics; Maxcyte; Merck; NextCure; Roche; Silverback Therapeutics; Takeda; Tempest Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Roche
Other Relationship - Aduro Biotech
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
David Miles
Honoraria - Roche/Genentech
Consulting or Advisory Role - Eisai; Roche/Genentech; Seagen
Travel, Accommodations, Expenses - Roche/Genentech
 
Sylvia Adams
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Merck
 
Stephen Y. Chui
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche/Genentech
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche
Research Funding - Genentech/Roche
Patents, Royalties, Other Intellectual Property - I am named on several patents for Genentech and Roche products, in my capacity as an employee of Genentech and Roche
Travel, Accommodations, Expenses - Genentech/Roche
Other Relationship - Genentech/Roche
 
Sanjeev Mariathasan
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Fabrice Andre
Stock and Other Ownership Interests - PEGASCY
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support